Observational studyOncology research2025

Disitamab Vedotin in HER2-Positive and HER2-Low Breast Cancer: A Multicenter Retrospective Analysis.

Xizhou Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.